Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature upgrades western blotting capability with Jess instrument from Protein Simple

Sygnature has upgraded its western blotting capability by investing in the Simple WesternTM Jess instrument from Protein Simple.

The device can be used on any project that monitors/measures protein expression level, providing better efficiency, higher-throughput, and higher quality data with better accuracy for quantification.

At Sygnature Discovery, we are always looking out for new technology and techniques that will allow us to support our clients’ drug discovery projects more effectively.

The Simple WesternTM system offers a more automated and higher-throughput approach to western blotting (which allows researchers to identify specific proteins from a complex mixture of proteins extracted from cells) by utilising the capillary based separation of protein targets by size.

The process removes the tradition hands-on gel and blotting steps and replaces these with automated separation and detection steps that enables data analysis after just three hours.

The Jess instrument allows the analysis of 24 samples per run with immunodetection available through one chemiluminescence and two fluorescence (IR and NIR) channels, enabling the multiplex analysis of different protein targets of interest from a single sample.

Further to this, protein normalisation can also be conducted without compromising on the available detection channels, measuring total protein content of the sample and allowing easy run-to-run comparison.

Applications include the quantification of target protein phosphorylation and DC50 and Dmax determination for targeted protein degradation assays. For more information about Sygnature’s experience in targeting the proteome see this article.

If you have any questions, or would like to discuss our capabilities, then we would love to hear from you. You can get in touch via the contact form.

Latest News

View All

New platform set to accelerate early-stage targeted…

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’